

REVIEW



The history of natural progesterone, the never-ending story

P. Piette

Consultant at Besins Healthcare Global, Department of R & D, Scientific & Medical Affairs, Brussels, Belgium

ABSTRACT

The term progesterone should only be used for the natural hormone produced by the ovaries or included in a registered drug. The modern history of progesterone begins with the first book-length description of the female reproductive system including the corpus luteum and later with the Nobel Prize winner, Adolf Butenandt who took a crucial step when he succeeded in converting pregnanediol into a chemically pure form of progesterone, the corpus luteum hormone. The deficient production of progesterone was shown first to be the cause of the luteal-phase deficiency responsible for infertility and early pregnancy loss due to inadequate secretory transformation of the endometrium. Later, progesterone was confirmed to be the best and safest method of providing luteal-phase support in assisted reproductive technology. Progesterone provides adequate endometrial protection and is suggested to be the optimal progestagen in menopausal hormone therapy in terms of cardiovascular effects, venous thromboembolism, probably stroke and even breast cancer risk. Neuroprotective effects of progesterone have also been demonstrated in several of experimental models including cerebral ischemic stroke and Alzheimer's disease. Vaginal progesterone was shown to decrease the risk of preterm birth in women with a mid-trimester sonographic short cervix and to improve perinatal outcomes in singleton and twin gestations.

ARTICLE HISTORY

Received 10 January 2018
Revised 30 March 2018
Accepted 5 April 2018
Published online 29 May 2018

KEYWORDS

Progesterone; allopregnanolone; pregnancy; miscarriage; hormone replacement therapy; luteal-phase support; preterm delivery

Introduction

There is a lot of confusion in the literature about natural progesterone, progestagens, progestogens and progestins. The term progesterone should only be used for the natural hormone produced by the ovaries or included in a registered drug, qualified as 'body identical' or 'bioidentical' and different from custom-compounded bioidentical hormones^{1,2}. It should never be used as a generic one to design different natural or synthetic compounds³. The functional terms 'progestogens' or 'progestagens' refer to natural or synthetic molecules with progestational activity, those which prepare the uterus for pregnancy. The term 'progestin' is used for synthetic compounds, designed to target the progesterone receptors, and belonging to different classes of molecules with sometimes very different pharmacological properties and modes of action⁴⁻⁶.

Progesterone in early pregnancy

In fact, the history of progesterone spans 500 million years and it is the oldest hormone that we know about⁷. However, the 'modern' history of progesterone begins with Regner de Graaf, a young Dutchman of Delft who published in 1672 his *De mulierum organis generation inservientibus*, the first book-length description of the female reproductive system, including the corpus luteum⁸.

In 1898, 226 years later, the French histologist Louis-Auguste Prenant and, at about the same time, the great

embryologist Gustav Born of Breslau suggested that the corpus luteum is an organ of internal secretion protecting the early embryo and facilitating its implantation in the uterus⁹. About 10 years later, the French embryologist Paul Ancel and the histologist Paul Bouin correctly supposed that the histological alterations of the endometrium that they had discovered were produced by endocrine activity of the corpus luteum¹⁰.

Finally, while working in Professor George Corner's US embryology laboratory, Professor Willard Allen, an organic chemist who went on to study medicine, discovered the hormone in the corpus luteum that sustained pregnancy and that was essential for survival of the preimplanted embryo in rabbits¹¹. It is noteworthy that the term 'hormone' was coined by the British physiologist Ernest Starling during one of his lectures in 1905, to define chemical signaling molecules produced by glands in multicellular organisms that are transported by the bloodstream to target distant organs and referring to a so-called endocrine mode of signaling¹².

The corpus luteum hormone was obtained in crystalline form from corpus luteum in 1931 and 1932 by various workers including Butenandt and Westphal in Danzig, Slotta in Breslau, and Hartmann and Wettstein in Switzerland⁹. It was isolated later by Allen in 1933¹³. Oscar Wintersteiner of New York completed the purification of Allen's progesterone and determined the empirical formula¹⁴.

In the autumn of 1934, Professor Adolf F. J. Butenandt and Schmidt succeeded in converting pregnanediol into a chemically pure form of the corpus luteum hormone, which

was given the name progesterone, a contraction of 'progestin' and 'luteo-sterone' in agreement with all the above contributors during a garden party given by the English pharmacologist Sir Henry Dale; he was Chairman of the conference of the Health Organization of the League of Nations (London, 1935) charged with setting up International Standards for some of the sex hormones including the new hormone of the corpus luteum¹⁴.

At the same time, Fernholz synthesized the hormone from stigmasterol but the production of this crystalline pure form was extremely difficult and time-consuming, and prices of progesterone were as high as \$1000 per gram¹⁵.

In 1939, the synthesis of this pregnancy hormone from cholesterol was carried out by Professor Adolf Butenandt in a straightforward way and he was awarded the same year, together with Leopold Ruzicka, the Nobel Prize in Chemistry for their work on sex hormones.

In 1938, Russell Earl Marker found that the sterol sarsapogenin from the *Sarsaparilla* plant could be converted into progesterone. However, sarsaparilla was expensive and, continuing his research, he isolated in 1941 a sterol, named diosgenin, extracted from the *Dioscorea* species of a yam growing wild in Mexico; this sterol could also be converted into progesterone using a technique which has since become known as the 'Marker degradation'¹⁵. After using a friend's lab to convert diosgenin into three kilograms of progesterone, he formed in 1944 the Syntex Company in Mexico City with two partners. Because of the low cost of Russell Marker's progesterone, it later became the preferred precursor to cortisone and, by 1951, Syntex developed the first oral contraceptive from progesterone¹⁶.

Georgeanna Seegar Jones, who became in 1949 the director of Johns Hopkins' Laboratory of Reproductive Physiology, was credited with using progesterone to treat women with a history of miscarriages, thus allowing many of them not only to conceive, but to deliver healthy babies. She was the first to describe luteal-phase deficiency, a cause of infertility and pregnancy loss caused by inadequate secretory transformation of the endometrium, resulting from deficient production of progesterone¹⁷. In 1978, when she and her husband left Hopkins for the Eastern Virginia Medical School

in Norfolk (EVMS), they created their own *in vitro* fertilization (IVF) program at EVMS. On December 28th, 1981, their procedure gave birth to Elizabeth Jordan Carr, the first American IVF baby after the birth of the first test-tube baby in the world, Louise Joy Brown, on July 25th, 1978 in England¹⁸.

Arpad Csapo claimed that progesterone both causes the uterus to prepare itself for pregnancy and guards the embryo against premature birth by inhibiting the contraction of uterine muscle. As a pioneer, he isolated actin and myosin, two proteins responsible for contractile properties of the muscle, and developed the theory that progesterone blocks the contraction of muscles in the pregnant uterus^{19,20}. However, until now there is no agreement on the exact nature of the physiological processes that control the onset of labor. He also found that early pregnancy luteectomy produces miscarriages through loss of progesterone support and that the contraction-blocking action of the progesterone shifted from the ovaries to the placenta, the so-called 'luteo-placental shift'^{21,22}.

Progesterone and brain

In the early 1940s too, it was shown by Hans Seyle that high doses of progesterone can very rapidly modulate brain excitability by inducing anesthesia in rats²³. In the 1970s, Karavolas and collaborators showed that progesterone was converted to 5 α -dihydroprogesterone and allopregnanolone within the rat hypothalamus and pituitary gland²⁴; in 1986 came the demonstration that both allopregnanolone (3 α ,5 α -tetrahydroprogesterone) and 3 α ,5 α -tetrahydrodeoxycorticosterone are natural positive modulators of neuronal GABA_A receptors, providing a mechanistic insight into the rapid psychopharmacological actions of progesterone and its metabolites, including anxiolytic, antidepressant, anesthetic, anticonvulsant, and analgesic effects²⁵.

In 2008, progesterone was suggested to act as a 'physiologic' regulator in case of sleep disturbances rather than as a hypnotic drug in aging and postmenopausal women, where sleep is fragmented and of lower quality (Figure 1)^{26,27}.




Figure 1. Sleep EEG parameters (minutes) before treatment (baseline), at day 21 placebo and day 21 oral progesterone treatment, 300 mg once a day in postmenopausal women. Total sleep time (TST) is the total time spent asleep. Sleep period time (SPT) is the time between sleep onset and last epoch of sleep in the morning. Awake SPT: awake corresponding to sleep period time. Data are given as mean \pm standard deviation. Adapted from Schüssler²⁶.

Neuroprotective effects of progesterone and allopregnanolone have been suggested in neonates²⁸ and demonstrated in many injury models, including cerebral ischemic stroke^{3,29}, excitotoxic damage of hippocampal neurons³⁰, traumatic spinal cord injury³¹, in mouse models of spontaneous spinal motoneuron degeneration and Alzheimer's disease^{32,33}. The view that the neuroprotective and regenerative effects of progesterone in the brain may be primarily mediated by allopregnanolone has recently been challenged by the observation that progesterone receptors play a key role in the viability of neurons after ischemic stroke and in the remyelination of axons after a demyelinating lesion^{29,34}, with also potential significant therapeutic implications in patients with multiple sclerosis and carpal tunnel syndrome³. Endogenous levels of progesterone were also found to correlate positively with factors predicting better prognosis and survival of patients with amyotrophic lateral sclerosis³⁵.

Progesterone in menopausal hormone therapy

In 1966, Robert A. Wilson's book informed women that menopausal symptoms were completely preventable, advising them to take estrogen with the promise of remaining '*Feminine forever*'. When it later became obvious that the risk of endometrial cancer was increased at least by 2.7 times in women treated with estrogen compared to untreated women, the medical community suggested progestagen to protect the uterus^{36–38}.

Initially, an oral formulation of progesterone was not used for menopausal hormone therapy (MHT) because of poor bioavailability, rapid hepatic metabolism and hence a rapid clearance rate. In the late 1970s, it was shown that decreasing the size of progesterone particles below 10 µm through micronization substantially increased the bioavailability of the hormone, partly suspended in peanut oil and partly in solution^{39,40}. The first approval for an oral progesterone capsule prepared by the Besins Company (France), under the brand Utrogestan[®], was granted in the early 1980s⁴¹. Interestingly, apart from its main progestational action, natural progesterone exerted antiandrogenic, antiminerocorticoid and neuroprotective, regenerative and sedative effects due to its unique pharmacodynamic profile^{4,42–44}.

In the meantime, synthetic analogs of progesterone were developed to make the hormone available orally for use as a contraceptive agent, but many of these compounds bound to receptors for glucocorticoids, androgen and mineralocorticoids, inducing possible side-effects such as acne, weight gain, depression, mood swings, irritability and increased breast cancer risk in MHT users. No synthetic progestin could mimic the same hormonal activities as the native progesterone hormone⁴¹.

In 1983, researchers led by Malcolm Whitehead at King's College Hospital Medical School (London) showed dose-dependent effects of oral progesterone on the estrogenized postmenopausal endometrium⁴⁵. Later, adequate endometrial protection was demonstrated in MHT when micronized progesterone was administered as a cyclic combined regimen (200 mg for 12 days each month) or as a continuous




Figure 2. Relative risks for invasive breast cancer by type of hormone replacement therapy (HRT) and progestogens compared with HRT never-use in the E3N cohort study. *Adjusted for time since menopause (time scale), age at menarche (<13/≥13 years old), parity and age at first full-term pregnancy (nulliparous/first full-term pregnancy at age <30, 1 or 2 children/first full-term pregnancy at age <30, 3 or more children/first full-term pregnancy at age ≥30), breastfeeding (no/<12 months/≥12 months/unknown), age at menopause (continuous), type of menopause (artificial/natural or unknown), personal history of benign breast disease (yes/no), family history of breast cancer in first-degree relatives (yes/no), family history of breast cancer in other relatives (yes/no), body mass index (≤20/[20–25]/[25–30]/>30 kg/m²), physical activity (<34/[34–47]/[47–62]/≥62 MET-h/week), previous mammography (yes/no, time-dependent variable). Further stratified on year of birth ([1925–1930]/[1930–1935]/[1935–1940]/[1940–1945]/[1945–1950]). **Other progestagens: medrogestone, chlormadinone acetate, cyproterone acetate, promegestone, nomegestrol acetate, norethisterone acetate, medroxyprogesterone acetate. Adapted from Fournier⁵⁷.

combined regimen of 100 mg per day, typically >2 years post final menstrual period^{46–50}. The same dose appeared to be devoid of side-effects on blood pressure, lipid profile and thrombotic risk, contrary to those caused by 19-nortestosterone derivatives and other synthetic progestins^{51–55}.

Finally, in a meta-analysis, observational studies suggested that, in menopausal women, use of estrogen and progesterone may be associated with lower breast cancer risk compared to synthetic progestin (Figure 2)⁵⁶. This systematic review was mainly based on the results of the E3N cohort study^{57,58} and supported by experimental evidence suggesting that the opposing effects of medroxyprogesterone acetate (MPA) and micronized progesterone on breast tissue are related to the non-specific effects of MPA, including glucocorticoid activity and differences in the regulation of gene expression^{50,59,60}.

Progesterone in luteal-phase deficiency and assisted reproductive technology

The premature onset of menses was recognized as indicative of a luteal-phase deficiency of progesterone production, which was shown to be correctable by exogenous progesterone administration¹⁷. The luteal phase in a natural cycle was defined as defective when serum mid-luteal progesterone levels decreased to less than 10 ng/ml, but it appeared very quickly that there was no correlation between plasma levels of progesterone, tissue levels and the histological pattern^{61,62}. The most reasonable consensus on a defective luteal phase was suggested as a lag of more than 2 days in endometrial histological development compared to the

expected day of the cycle, based on the criteria of Noyes, even if there was delayed endometrial development in the luteal phase in about one-quarter of women⁶².

In the early 1980s, two famous pioneers in IVF, Robert G. Edwards in Europe and Howard W. Jones in the US reported a shortened luteal phase when human menopausal gonadotropins (hMG) alone were used to induce multiple follicular growth for *in vivo* and *in vitro* fertilization. The use of gonadotropin-releasing hormone agonists for a combined therapy with hMG suppressed the output of preovulatory luteinizing hormone (LH), deleterious for embryo quality; supraphysiological levels of steroids such as estradiol, secreted by a high number of corpora lutea during the early luteal phase of stimulated cycles, inhibited the LH release via negative feedback actions at the level of the hypothalamic–pituitary axis, inducing premature luteolysis^{63,64}. Because LH support during the early luteal phase is entirely responsible for the maintenance and the normal steroidogenic activity necessary to prepare the endometrium for embryo implantation, low implantation and pregnancy rates were observed if no adequate exogenous luteal-phase support (LPS) was provided⁶⁴.

Progesterone was recognized to be the best method of providing LPS in assisted reproduction technology (ART), as it was associated with higher rates of live birth or ongoing pregnancy than placebo, with lower rates of ovarian hyperstimulation syndrome⁶⁵. Based on an updated world-wide web-based survey obtained from 408 centers (82 countries), representing 284 600 IVF cycles/year, and assessing the real-life clinical practices regarding LPS, most practitioners (80% of cycles) started LPS on the day of egg collection; a vaginal progesterone product was used in >90% (77% as a single agent and 17% in combination with intramuscular progesterone), and administered until 8–10 weeks' gestation or beyond. The most commonly used vaginal progesterone preparation was a vaginal tablet, preferred in 46% of cycles⁶⁶.

The vaginal progesterone capsule is supported now by more than 20 years of evidence from randomized controlled trials in about 6000 patients, providing optimal ongoing pregnancy and live birth rates in ART procedures with a level 1 of evidence.

Progesterone in prevention of preterm birth

Preterm delivery is a leading cause of neonatal morbidity and mortality⁶⁷. In 2010, an estimated 14.9 million babies were born preterm, 11.1% of all livebirths world-wide⁶⁸. Preterm parturition is a syndrome caused by multiple etiological factors such as intra-amniotic infection, extrauterine infections, vascular disorders, decidual senescence, disruption of maternal–fetal tolerance, a decline in progesterone action, uterine overdistension, cervical disease, or maternal stress⁶⁹.

Even if Emile Papiernik in France was the first in 1970 to suggest progesterone for the prevention of preterm birth⁷⁰, it took another 30 years before two trials confirmed that daily vaginal progesterone administration (100 mg between 24 and 34 weeks of gestation) and weekly injections of 17 α -hydroxyprogesterone caproate (250 mg intramuscularly

between 16 and 36 weeks) reduced the rate of preterm birth (≤ 37 weeks)^{6,70,71}.

A short cervix, conventionally defined as a transvaginal sonographic cervical length ≤ 25 mm in the midtrimester of pregnancy, and a history of spontaneous preterm birth to a lesser extent, are powerful risk factors for spontaneous preterm birth; they have a high predictive accuracy for spontaneous preterm birth at <34 weeks of gestation, and a moderate to low predictive accuracy for spontaneous preterm birth at <37 weeks of gestation in both singleton and twin gestations^{72,73}. In two meta-analyses of individual patient data, vaginal progesterone decreased the risk of preterm birth in women with a midtrimester sonographic short cervix^{74,75}, was cost-effective and improved perinatal outcomes in singleton and twin gestations, without any demonstrable deleterious effects on childhood neurodevelopment^{28,76,77}.

Conclusion and future directions

Natural 'body-identical' oral progesterone is devoid of any androgenic and glucocorticoid activities, it is slightly hypotensive due to its antimineralocorticoid activity, and it appears to be the optimal progestogen, in synergism with estrogen, in MHT in terms of cardiovascular effects, blood pressure, venous thromboembolism, probably stroke and even breast cancer risk, as opposed to synthetic progestagens and particularly MPA, which appear to be mitogenic on breast cells^{2,78}. Further studies will contribute to a better understanding of the effects of progesterone on some target tissues such as the breast. The risk of breast cancer attributable to MHT is small, it decreases progressively after treatment is stopped and it may be lower with micronized progesterone than with synthetic progestins⁶³. However, the risk of breast cancer associated with MHT in women over 50 years remains a complex issue, probably related also to duration of use.

Progesterone has both unpredictable proliferative and differentiating actions on normal and breast cancer tissue. Identification of genes whose transcription is directly modulated by progesterone is a crucial step in understanding the effects of progesterone on these complex processes⁴⁵.

It is suggested, for example, that the progesterone receptor (PR) is an estrogen receptor- α (ER α)-associated protein that may function as a molecular rheostat to control ER α chromatin binding and transcriptional activity within breast cancer cells, with a possible good clinical outcome in the presence of agonist ligands obtained with a unique gene expression program. Progesterone inhibits estrogen-mediated growth of ER α ⁺ cell-line xenografts and primary ER α ⁺ breast tumor explants, and increases antiproliferative effects when coupled with an ER α antagonist⁷⁹.

As a first step to validate this hypothesis, ongoing trials will evaluate whether treatment with oral progesterone in combination with ER-directed therapy, such as tamoxifen, will result in a significant reduction in the proliferation marker Ki-67 by immunohistochemistry in women with ER-positive, PR-positive, HER2-negative breast cancer.

Recent improvements in freezing embryos and oocytes in more user-friendly ART, including vaginal progesterone for luteal-phase support, represent a real breakthrough in reproductive biology without jeopardizing the best chances of success, giving the opportunity to move away from the standard sequence of ovarian stimulation–retrieval–transfer and constraints associated with the potential harmful effects of the hormonal environment on endometrial receptivity and those associated with the risk of ovarian hyperstimulation syndrome⁸⁰. However, more research is needed with randomized controlled trials and medico-economic studies with a sufficient number of patients, to confirm the outcomes in new protocols, e.g. using vaginal progesterone in the follicular phase to block the LH surge. During frozen–thawed embryo transfer cycles, the optimal dose, timing, duration and cost-effectiveness of vaginal progesterone for luteal-phase support remain to be further evaluated in well-designed, comparative, randomized controlled trials.

Since the early 1970s and first evidences by Papiernik and Csapo suggesting progesterone for early implantation, pregnancy maintenance, prevention of early or late miscarriage and prevention of preterm birth, there remain important questions unanswered, e.g. how a shift in the estrogen/progesterone ratio is achieved and how estrogen and progesterone signaling interacts at the level of the cervical cells before the onset of labor⁸¹. Therefore, in symptomatic women undelivered after an episode of preterm labor, the efficacy of progesterone to prevent preterm birth remains to be clarified⁸².

For sure, previous and future clinical developments with progesterone are indeed a never-ending story.

Conflict of interest P. Piette is a Consultant at Besins Healthcare Global, and Senior Research Fellow (Scientific and Medical Affairs Director).

Source of funding Nil.

References

- Panay N. Body identical hormone replacement. *Post Reprod Health* 2014;20:69–72
- L'Hermite M. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal. *Climacteric* 2017;20:331–8
- Schumacher M, Mattern C, Ghomari A, et al. Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors. *Prog Neurobiol* 2014;113:6–39
- Schumacher M, Guennoun R, Ghomari A, et al. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. *Endocr Rev* 2007;28:387–439
- Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr, Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. *Endocr Rev* 2013;34:171–208
- Sitruk-Ware R. Pharmacological profile of progestins. *Maturitas* 2008;61:151–7
- <http://www.progesteronetherapy.com/history-of-progesterone.html>. 2010.
- Graaf, de. De mulierum organis generation inservietibus. Lugduni Batavorum, ex. off. Hackiana; 1672
- Corner GW. The early history of progesterone. *Gynecol Invest* 1974;5:106–12
- Bouin P, Ancel P. Sur le déterminisme de la préparation de l'utérus à la fixation de l'oeuf. *J Physiol Pathol Gen* 1910;12:1–16
- Allen WM. Physiology of the corpus luteum. V. The preparation and some chemical properties of progestin, a hormone of the corpus luteum which produces progestational proliferation. *Am J Physiol* 1930;92:174–88
- Starling EH. Croonian lecture: on the chemical correlation of the functions of the body. *Lancet* 1905;2:339–41
- Allen WM. The preparation of purified progestin. *J Biol Chem* 1932;98:581–605
- Allen WM. Recollections of my life with progesterone. *Gynecol Invest* 1974;5:142–82
- Newton SJ. The history of progesterone. *Int J Pharm Compd* 2007;11:274–7
- American Chemical Society International Historic Chemical Landmarks. The “Marker Degradation” and Creation of the Mexican Steroid Hormone Industry 1938–1945. Available from: <http://www.acs.org/content/acs/en/education/whatischemistry/landmarks/progesteronesynthesis.html>. 1999.
- Jones GE. Some newer aspects of the management of infertility. *J Am Med Assoc* 1949;141:1123–19
- Damewood MD, Rock JA. In memoriam: Georgeanna Seegar Jones, M.D.: her legacy lives on. *Fertil Steril* 2005;84:541–2
- Csapo AI. Actomyosin content of the uterus. *Nature* 1948;162:218–19
- Csapo AI, Pinto-Dantas CA. The effect of progesterone on the human uterus. *Proc Natl Acad Sci USA* 1965;54:1069–76
- Csapo AI, Pulkkinen MO, Wiest WG. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. *Am J Obstet Gynecol* 1973;115:759–65
- Csapo AI. The luteo-placental shift, the guardian of pre-natal life. *Postgrad Med J* 1969;45:57–64
- Seyle H. Correlations between the chemical structure and pharmacological actions of the steroids. *Endocrinology* 1942;30:437–53
- Karavolas HJ, Hodges D, O'Brien D. Uptake of (3H) progesterone and (3H)5alpha-dihydroprogesterone by rat tissues in vivo and analysis of accumulated radioactivity: accumulation of 5alpha-dihydroprogesterone by pituitary and hypothalamic tissues. *Endocrinology* 1976;98:164–75
- Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. *Science* 1986;232:1004–7
- Schüssler P, Kluge M, Yassouridis A, et al. Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. *Psychoneuroendocrinology* 2008;33:1124–31
- Caufriez A, Leproult R, L'Hermite-Balériaux M, Kerkhofs M, Copinschi G. Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women. *J Clin Endocrinol Metab* 2011;96:e614–23
- Vedel C, Larsen H, Holmskov A, et al. Long-term effects of prenatal progesterone exposure: neurophysiological development and hospital admissions in twins up to 8 years of age. *Ultrasound Obstet Gynecol* 2016;48:382–9
- Liu A, Margail I, Zhang S, et al. Progesterone receptors: a key for neuroprotection in experimental stroke. *Endocrinology* 2012;153:3747–57
- Ciriza I, Azcoitia I, Garcia-Segura LM. Reduced progesterone metabolites protect rat hippocampal neurones from kainic acid excitotoxicity in vivo. *J Neuroendocrinol* 2004;16:58–63
- De Nicola AF, Labombarda F, Deniselle MC, et al. Progesterone neuroprotection in traumatic CNS injury and motoneuron degeneration. *Front Neuroendocrinol* 2009;30:173–87
- Gonzalez Deniselle MC, Gonzalez S, De Nicola AF. Cellular basis of steroid neuroprotection in the wobbler mouse, a genetic model of motoneuron disease. *Cell Mol Neurobiol* 2001;21:237–54
- Wang JM, Singh C, Liu L, et al. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. *Proc Natl Acad Sci USA* 2010;107:6498–503

34. Hussain R, el-Etr M, Gaci O, et al. Progesterone and nestorone facilitate axon remyelination: a role for progesterone receptors. *Endocrinology* 2011;152:3820–31
35. Gargiulo Monachelli G, Meyer M, Rodriguez GE, et al. Endogenous progesterone is associated to amyotrophic lateral sclerosis prognostic factors. *Acta Neurol Scand* 2011;123:60–7
36. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. *N Engl J Med* 1975;293:1164–7
37. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. *N Engl J Med* 1975;293:1167–70
38. Gambrell RD, Jr., Massey FM, Castaneda TA, Ugenas AJ, Ricci CA. Reduced incidence of endometrial cancer among postmenopausal women treated with progestogens. *J Am Geriatr Soc* 1979;27:389–94
39. Morville R, Dray F, Reynier J, Barrat J. [The bioavailability of natural progesterone given by mouth. Measurement of steroid concentrations in plasma, endometrium and breast tissue]. *J Gynecol Obstet Biol Reprod* 1982;11:355–63
40. Hargrove JT, Maxson WS, Wentz AC. Absorption of oral progesterone is influenced by vehicle and particle size. *Am J Obstet Gynecol* 1989;161:948–51
41. Sitruk-Ware R, Bricaire C, De Lignieres B, Yaneva H, Mauvais-Jarvis P. Oral micronized progesterone. Bioavailability pharmacokinetics, pharmacological and therapeutic implications-a review. *Contraception* 1987;36:373–402
42. Corvol P, Elvik F, Feneant M, et al. Effect of progesterone and progestins on water and salt metabolism. In: Bardin CW, Milgrom E, Mauvais-Jarvis P, eds. *Progesterone and progestins*. New York: Raven Press; 1983:179–86
43. Dennerstein L, Spencer-Gardner C, Gotts G, Brown JB, Smith MA, Burrows GD. Progesterone and the premenstrual syndrome: a double-blind crossover trial. *Br Med J* 1985;290:1617–21
44. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. *Endocr Rev* 1997;18:502–19
45. Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJ, Whitehead MI. Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium. *Br Med J* 1983;287:1241–5
46. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. *JAMA* 1996;275:370–5
47. Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. *Climacteric* 2016;19:316–28
48. Baber RJ, Panay N, Fenton A. the IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. *Climacteric* 2016;19:109–50
49. Eden J. The endometrial and breast safety of menopausal hormone therapy containing micronised progesterone: a short review. *Aust N Z J Obstet Gynaecol* 2017;57:12–15
50. Gompel A. Micronized progesterone and its impact on the endometrium and breast vs. progestogens. *Climacteric* 2012;15(Suppl 1):18–25
51. Rylance PB, Brincat M, Lafferty K, et al. Natural progesterone and antihypertensive action. *Br Med J (Clin Res Ed)* 1985;290:13–14
52. Boschitsch E, Mayerhofer S, Magometschnigg D. Hypertension in women: the role of progesterone and aldosterone. *Climacteric* 2010;13:307–13
53. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. *JAMA* 1995;273:199–208
54. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. *Arterioscler Thromb Vasc Biol* 2010;30:340–5
55. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. *Circulation* 2007;115:840–5
56. Asi1 N, Mohammed K, Haydour Q, et al. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. *Syst Rev* 2016;5:121–8
57. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. *Breast Cancer Res Treat* 2008;107:103–11
58. Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. *Clin Oncol* 2008;26:1260–8
59. Murkes D, Lalitkumar PG, Leifland K, Lundström E, Söderqvist G. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo. *Gynecol Endocrinol* 2012;28(Suppl 2):12–15
60. Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. *Climacteric* 2012;15:241–9
61. Jordan J, Craig K, Clifton DK, Soules MR. Luteal phase defect: the sensitivity and specificity of diagnostic methods in common clinical use. *Fertil Steril* 1994;62:54–62
62. Bourgain C, Smitz J, Camus M, et al. Human endometrial maturation is markedly improved after luteal supplementation of gonadotrophin-releasing hormone analogue/human menopausal gonadotrophin stimulated cycles. *Hum Reprod* 1994;9:32–40
63. Smitz J, Devroey P, Van Steirteghem AC. Endocrinology in luteal phase and implantation. *Br Med Bull* 1990;46:709–19
64. Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P. An update of luteal phase support in stimulated IVF cycles. *Hum Reprod Update* 2007;13:581–90
65. van der Linden M, Buckingham K, Farquhar C, Kremer JAM, Metwally M. Luteal phase support for assisted reproduction cycles. *Cochrane Database Syst Rev* 2015;7:CD009154
66. Vaisbuch E, de Ziegler D, Leong M, Weissman A, Shoham Z. Luteal-phase support in assisted reproduction treatment: real-life practices reported worldwide by an updated website-based survey. *Reprod Biomed Online* 2014;28:330–5
67. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. *Am J Obstet Gynecol* 2003;188:419–24
68. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. *Lancet* 2012;379:2162–72
69. Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. *Science* 2014;345:760–5
70. Papiernik-Berkhauer E. Étude en double aveugle d'un médicament prévenant la survenue prématurée de l'accouchement chez les femmes « à risque élevé » d'accouchement prématuré. In Edition Schering, Série IV, fiche 3. 1970
71. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. *N Engl J Med* 2003;348:2379–85
72. Conde-Agudelo A, Romero R, Hassan SS, Yeo L. Transvaginal sonographic cervical length for the prediction of spontaneous preterm birth in twin pregnancies: a systematic review and metaanalysis. *Am J Obstet Gynecol* 2010;203:128.e1–12
73. Conde-Agudelo A, Romero R. Predictive accuracy of changes in transvaginal sonographic cervical length over time for preterm birth: a systematic review and metaanalysis. *Am J Obstet Gynecol* 2015;213:789–801
74. Romero R, Conde-Agudelo A, Da Fonseca E, et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. *Am J Obstet Gynecol* 2018;218:161–80

75. Romero R, Conde-Agudelo A, El-Refaie W, *et al.* Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. *Ultrasound Obstet Gynecol* 2017;49:303–14
76. McNamara HC, Wood R, Chalmers J, *et al.* STOPPIT Baby Follow-up Study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. *PLoS One* 2015;10:e0122341
77. Schuit E, Stock S, Rode L, *et al.* Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis. *BJOG* 2015;122:27–37
78. Harman SM, Black DM, Naftolin F, *et al.* Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. *Ann Intern Med* 2014;161:249–60
79. Mohammed H, Russell IA, Stark R, *et al.* Progesterone receptor modulates ER α action in breast cancer. *Nature* 2015; 523:313–17
80. Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. *Hum Reprod Update* 2017;23:211–20
81. Wagner GP, Nnamani MC, Chavan AR, *et al.* Evolution of gene expression in the uterine cervix related to steroid signaling: conserved features in the regulation of cervical ripening. *Sci Rep* 2017;7:4439–50
82. Di Renzo GC, Cabero Roura L, Facchinetti F, *et al.* Preterm labor and birth management: Recommendations from the European Association of Perinatal Medicine. *J Matern Fetal Neonatal Med* 2017;30:2011–30